This study aims to observe the effects of low-dose IL-2 combined with TCZ on arthritis symptoms and immune cells in active RA patients, based on the good results of low-dose IL-2 combined with bDMARDs, excluding TCZ, reported in previous studies (25, 26). Here, IL2 is linked to arthritic joint disease.